Jim Breitmeyer, MD, PhD

Jim Breitmeyer is the CEO of Oncternal Therapeutics, a clinical-stage oncology company. Prior to this, he was President of Bavarian Nordic Inc. in the US & Executive Vice President of Bavarian A/S, headquartered in Denmark. He is on the Board of Directors of Zogenix, Inc. and until 2012 was Executive Vice President of Development and Chief Medical Officer of Cadence Pharmaceuticals Inc. Jim was Chief Medical Officer of Applied Molecular Evolution Inc., a wholly-owned subsidiary of Eli Lilly and Co. He also served as the President and CEO of the Harvard Clinical Research Institute. Jim also held a variety of positions at Serono Laboratories Inc. Prior to Serono, he served as a founding collaborator and scientific advisor to Immunogen Inc., and held clinical and teaching positions at the Dana Farber Cancer Institute and Harvard Medical School. Jim has a BA in Chemistry from the University of California, Santa Cruz and a M.D. and Ph.D. from Washington University School of Medicine, and is Board Certified in Internal Medicine & Oncology.

Martin Leblanc, MA
Martin Leblanc is the CEO of Caprion Proteomics, a leading provider of proteomics and immune monitoring services to the Pharmaceutical and Biotechnology industry, with the majority of its business in immuno-oncology. With its GLP and GCLP accredited laboratories in Canada and Belgium, Caprion has been providing large-scale proteomics and immune monitoring services to over 60 major Pharmaceutical and Biotech clients for more than 15 years. Prior to Caprion, he was successively a management consultant with McKinsey & Company, VP of Sales & Marketing at Advanced Bioconcept Ltd. and its General Manager after its acquisition by NEN Life Sciences (now Perkin-Elmer). Martin is also a member of the Board of Directors of Victhom Human Bionics, Montréal InVivo, the Atlantic Cancer Research Institute, the Canadian Institute of Health Research (CIHR) and Soricimed. Martin was a Rhodes Scholar, obtaining an MA in Economics and Politics from Oxford University.

Nicola Urbani, PhD, MBA
Nicola Urbani is an investor at the venture capital fund Emerillon Capital. Prior to that he was at the venture capital fund GeneChem. He has been actively involved in the growth of several companies developing therapeutics through human clinical trials, and led several in- and out-licensing deals in Life Sciences and cleantech. Nicola has a PhD in molecular genetics from McGill University and an MBA from University of Quebec at Montreal.

Mark de Groot, PhD

Chief Executive Officer and Chairman

Uri Saragovi, PhD

Chief Scientific Officer